JN Atkins

637 total citations
22 papers, 500 citations indexed

About

JN Atkins is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, JN Atkins has authored 22 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in JN Atkins's work include Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Breast Cancer Treatment Studies (6 papers). JN Atkins is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Breast Cancer Treatment Studies (6 papers). JN Atkins collaborates with scholars based in United States, Italy and Canada. JN Atkins's co-authors include Norman Wolmark, M J O'Connell, Séamus O’Reilly, Greg Yothers, Saima Sharif, C. Klabunde, Carmen J. Allegra, Ramaswamy Govindan, Mark A. Socinski and Silvia Novello and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

JN Atkins

21 papers receiving 482 citations

Peers

Countries citing papers authored by JN Atkins

Since Specialization

Citations

This map shows the geographic impact of JN Atkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by JN Atkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites JN Atkins more than expected).

Fields of papers citing papers by JN Atkins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by JN Atkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by JN Atkins. The network helps show where JN Atkins may publish in the future.

Co-authorship network of co-authors of JN Atkins

This figure shows the co-authorship network connecting the top 25 collaborators of JN Atkins. A scholar is included among the top collaborators of JN Atkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with JN Atkins. JN Atkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC) 2018 ·Cancer Research ·L. Fehrenbacher, (unknown), CE Geyer, Priya Rastogi, J. P. Costantino, JN Atkins, Jonathan Polikoff, (unknown), Louise Provencher, Christopher Stokoe, (unknown), A. Robidoux, Virginia F. Borges, KS Albain, SM Swain, Soonmyung Paik, EP Mamounas, Norman Wolmark	40
2	NRG Oncology/RTOG 0937: Randomized Phase 2 Study Comparing Prophylactic Cranial Irradiation (PCI) Alone to PCI and Consolidative Extracranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC) 2015 ·International Journal of Radiation OncologyBiologyPhysics ·Elizabeth Gore, Chen Hu, A. Sun, Daniel Grimm, Suresh S. Ramalingam, Neal Dunlap, Kristin Higgins, Maria Werner‐Wasik, Aaron M. Allen, Puneeth Iyengar, Gregory M.M. Videtic, Russell K. Hales, R.C. McGarry, James J. Urbanic, Anthony T. Pu, Candice Johnstone, JN Atkins, J.D. Bradley	10
3	OT1-02-05: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy to Radiation Therapy (RT) Alone for Women with HER2−Positive DCIS Resected by Lumpectomy: NSABP B-43. 2011 ·Cancer Research ·TB Julian, (unknown), (unknown), (unknown), D.W. Arthur, Ping Zheng, EP Mamounas, (unknown), (unknown), Laura Chu, (unknown), JN Atkins, Jonathan Polikoff, (unknown), Worta McCaskill‐Stevens, (unknown), Norman Wolmark	3
4	Abstract S6-3: Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes: CALGB 40101 — A 2x2 Factorial Phase III Trial: First Results Comparing 4 vs 6 Cycles of Therapy 2010 ·Cancer Research ·L. Shulman, C. Cirrincione, DA Berry, (unknown), (unknown), (unknown), Simona Di Martino, JN Atkins, Clifford A. Hudis, EP Winer	4
5	A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08 2009 ·Journal of Clinical Oncology ·Norman Wolmark, Greg Yothers, M J O'Connell, Saima Sharif, JN Atkins, (unknown), (unknown), Séamus O’Reilly, Carmen J. Allegra	102
6	Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206 2009 ·Journal of Clinical Oncology ·Brian I. Rini, Susan Halabi, Jacob Rosenberg, Walter M. Stadler, Daniel A. Vaena, JN Atkins, Joel Picus, Piotr Czaykowski, (unknown), Eric J. Small	7
7	NSABP B-30: definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. 2009 ·Cancer Research ·SM Swain, Joon Jeong, CE Geyer, J. P. Costantino, (unknown), L. Fehrenbacher, JN Atkins, Jonathan Polikoff, (unknown), (unknown), R. B. Livingston, EA Perez, EP Mamounas, PA Ganz, (unknown), Norman Wolmark	21
8	Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206 2009 ·Journal of Clinical Oncology ·Brian I. Rini, Susan Halabi, Jonathan E. Rosenberg, Walter M. Stadler, Daniel A. Vaena, JN Atkins, Joel Picus, Piotr Czaykowski, Janice P. Dutcher, Eric J. Small	36
9	NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. 2009 ·Cancer Research ·PA Ganz, (unknown), CE Geyer, J. P. Costantino, (unknown), L. Fehrenbacher, JN Atkins, (unknown), (unknown), (unknown), R. B. Livingston, EA Perez, EP Mamounas, Norman Wolmark, SM Swain	3
10	LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402 2008 ·Journal of Clinical Oncology ·Allyson J. Ocean, Donna Niedzwiecki, JN Atkins, (unknown), Bert H. O’Neil, (unknown), Scott Wadler, Richard M. Goldberg	10
11	6525 POSTER Phase II study investigating the efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC) 2007 ·European Journal of Cancer Supplements ·Ramaswamy Govindan, Julie R. Brahmer, Silvia Novello, Rafael Rosell, Chandra P. Belani, JN Atkins, (unknown), L. Tye, Richard C. Chao, (unknown)	1
12	CALGB 30206: Phase II study of induction cisplatin (P) and irinotecan (I) followed by combination carboplatin (C), etoposide (E), and thoracic radiotherapy for limited stage small cell lung cancer 2007 ·Journal of Clinical Oncology ·Michael J. Kelley, Jeffrey A. Bogart, (unknown), Rafat Ansari, JN Atkins, (unknown), (unknown), Everett E. Vokes	6
13	Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non–Small-Cell Lung Cancer (NSCLC) 2007 ·Clinical Lung Cancer ·Giorgio V. Scagliotti, (unknown), Julie R. Brahmer, Ramaswamy Govindan, Rafael Rosell, Chandra P. Belani, JN Atkins, L. Tye, Richard C. Chao, Mark A. Socinski	1
14	Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial 2006 ·Journal of Clinical Oncology ·Mark A. Socinski, Silvia Novello, J. M. Sanchez, (unknown), Ramaswamy Govindan, Chandra P. Belani, JN Atkins, (unknown), (unknown), Richard C. Chao	79
15	Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM) 2004 ·Journal of Clinical Oncology ·Linda L. Garland, Cathryn Rankin, Katherine Scott, Raymond B. Nagle, Michael Lobell, David R. Gandara, Saul E. Rivkin, Wolfram E. Samlowski, JN Atkins, Ernest C. Borden	12
16	Molecular correlates of the EGFR signaling pathway in association with SWOG S0218: a phase II study of oral EGFR tyrosine kinase inhibitor OSI-774 (NSC-718781) in patients with malignant pleural mesothelioma (MPM) 2004 ·Journal of Clinical Oncology ·Linda L. Garland, Cathryn Rankin, Katherine Scott, Raymond B. Nagle, Michael Lobell, David R. Gandara, Saul E. Rivkin, Wolfram E. Samlowski, JN Atkins, Ernest C. Borden	3
17	Phase II study of postoperative adjuvant therapy in patients with completely resected stage II and IIIA non-small cell lung cancer (RTOG 97-05) 2001 ·International Journal of Radiation OncologyBiologyPhysics ·David S. Ettinger, (unknown), Jeffrey D. Bradley, M.V. Pilepich, Mitchell Machtay, Ritsuko Komaki, JN Atkins, Walter J. Curran, Michael M. Graham	4
18	A phase III randomized study of carboplatin and paclitaxel with or without amifostine in patients with non-small cell lung cancer (NSCLC) 2000 ·Lung Cancer ·Chandra P. Belani, Rafat Ansari, JN Atkins, Jeremy K. Hon, Manuel Modiano, Thomas Budd	1
19	Factors Influencing Enrollment in Clinical Trials for Cancer Treatment 1999 ·Southern Medical Journal ·C. Klabunde, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), JN Atkins	88
20	Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: a Piedmont Oncology Association study. 1994 ·Journal of Clinical Oncology ·Hyman B. Muss, L. Douglas Case, JN Atkins, James D. Bearden, M. Robert Cooper, J M Cruz, Don V. Jackson, Mark Allen O’Rourke, (unknown), Bayard L. Powell	53

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact